Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...
Engineered CAR‑T cells suppressed HIV off medication in two people — promising but early. Larger trials are needed.
Colleen Mabasa reflected on the importance of self-advocacy, as well as seeking second opinions and ensuring patients understand all available options. Colleen Mabasa, a patient with multiple myeloma, ...
Targeting KMA seeks to spare normal immunoglobulin-producing plasma cells, differentiating from BCMA-directed CAR T ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Regulatory trials of chimeric antigen receptor T-cell therapies for autoimmune diseases could be ...
Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell ...
Please provide your email address to receive an email when new articles are posted on . Patients who would not have been eligible for pivotal CAR-T trials may still derive benefit from the therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results